Introduction
Leptospirosis is a worldwide amphixenosis caused by pathogenic leptospires. Human leptospirosis is often contracted through contact with infected animals or by exposure to water, moist soil, or vegetation contaminated by the urine of shedding animals (1) . Leptospirosis is most commonly found in tropical and rural areas. The burden imposed by this disease is unknown, yet it is widely recognized that its incidence is remarkably underestimated and the disease underdiagnosed in endemic regions. It is estimated to affect tens of millions of people annually (2) . In its acute form, it may affect multiple organs including the liver (jaundice), kidneys (nephritis), lungs (pulmonary hemorrhage), and brain (meningitis), all of which may lead to multi-organ failure. Furthermore, it may cause death in 5-10% of human cases (3) . In livestock, Leptospira infection is associated with abortion, stillbirth, milk drop syndrome, and sometimes even death (4) . The medical and economic losses caused by such forms of the disease justify the use of Leptospira vaccines in human and animal populations.
The currently available leptospirosis vaccine is an inactivated whole cell product that provides inadequate protection against the common serovars. In addition, it cannot provide cross-protection against the large number of pathogenic leptospires serogroups (5) . Thus, new vaccine strategies are needed for the prevention of leptospirosis. It is recognized that Plasmid DNA vaccines are promising modalities for immunization against a variety of human pathogens. Immunization via multiple routes with plasmid DNA can elicit potent cellular immune responses. Additionally, these immunogens can be administered repeatedly without inducing anti-vector immunity (6). 5 These authors contributed equally to this work; LipL21 is the second major outer membrane protein in Leptospira interrogans serovar Lai, which has exhibited potent immunity capabilities (7) , indicating that the lipL21 gene is a potent candidate gene for the prevention of the disease. Therefore, we initially constructed eukaryotic expression vector pcDNA3.1(+)-lipL21 and subsequently tested the effect of recombinant vector's immunization.
Materials and Methods

Animals
Six-week-old male guinea pigs (weight of 250-280 g, Grade III, Certificate 2005B067) bred in our laboratory were used in this study. The animals were purchased from the Animal Practices Center of Nanhua University a week before the experiment and raised at a 12 h light/dark cycle photoperiod, provided with solid chow and water ad libitum. Strain L. interrogans serovar Lai strain 56601 was purchased from the Hunan provincial disease control center. Leptospires were grown in Korthof medium at 29°C as estimated by turbidimetry with a calibrated Hach apparatus. Typically, 100 turbidimetric units are equivalent to 2 × 10 8 to 5 × 10 8 leptospires/ml. They were harvested when the concentration reached 100 turbidimetric units after centrifugation for 30 min at 12,000 g. Thereafter, the bacteria were resuspended in Laemmli sample buffer containing 2% 2-mercaptoethanol.
Reagents
PCRII.1 vector and pcDNA3.1(+) vector were purchased from Invitrogen (Carlsbad, CA, USA), while EcoR I, Xho I, T4 DNA ligase, PyroBest DNA polymerase, and dNTP were purchased from Takara (Dalian, China). The agarose gel DNA purification system was purchased from Shanghai Biotechnology Co. (Shanghai, China), and the HRP-conjugated goat anti-rabbit immunoglobulin G was bought from Bosside (Wuhan, China). Endotoxin-free plasmid extraction kit was obtained from QIAGEN (Germany). COS-7 cells were stored in our laboratory. ECL Western blot detection reagents were purchased from Amersham Bioscience (Piscataway, NJ, USA). Diaminobenzidine (DAB), phytohaemagglutinin (PHA) and other chemicals were of analytical reagent grade.
PCR amplification of lipL21
The genomic DNA of L. interrogans strain 56601 was used as template for PCR isolation of the target sequence. The primer was designed according to the lipL21 (Lai) full gene published by Genbank (GI: 30171159). The sequence of the forward primer for lipL21 was 5'-CGG AAT TCA TGA TCA ATA GAC TTA TAG CTC-3'. This primer has a 6-bp sequence (underlined) at the 5' end to create an EcoR I site. The sequence of the reverse primer was 5'-CCC GAG CTC TTA TTG TTT GGA AAC CTC TTG A-3'. This primer has a sequence (underlined) at the 5' end to create an Xho I site. A 50 μl reaction mixture containing 2 μl of genomic DNA, 1 μl 50 mM primers, 4 μl dNTPs (2.5 mM each dNTP), 5 μl 10× pyrobest buffer, and 0.4 μl pyrobest DNA polymerase (5 U/μl) was used. The PCR program was as follows: firstly, denaturation at 94°C for 5 min; secondly, 33 cycles of denaturation at 94°C for 1 min, annealing at 52°C for 1 min, and extension at 72°C for 1.5 min; finally, extension at 72°C for 10 min. The amplifications were analyzed through electrophoresis on a 1.2% agarose gel stained by ethidium bromide. Then, the DNA was purified using the agarose gel DNA purification system.
Construction of pcDNA3.1(+)-lipL21 expression vectors
Plasmid DNA preparation and restriction enzyme digestion were performed under standard conditions. The PCR product was cloned by TA cloning in the PCRII.1 vector, which generated PCRII.1-lipL21. Then, the DNA insert was sequenced (Takara, Dalian, China). PCRII.1-lipL21 was digested and ligated into the EcoR I and Xho I sites of a pcDNA3.1(+) vector, generating pcDNA-lipL21. The sequence of lipL21 in the vector was identical with the lipL21 gene sequence in GenBank (GI: 30171159). Another vector without any foreign sequence was used as control. Large-scale plasmid production was performed with an Endotoxin-free plasmid extraction kit. Plasmid stocks were stored at -20°C in PBS without calcium. These plasmids were used for in vitro transfection and vaccination studies.
Transfection and visualization of expressed antigens
To confirm that various DNA constructs were functional and to determine the efficiency of protein expression, COS-7 cells were transfected with the plasmid pcDNA3.1(+)-lipL21 using lipsome. Transfection with an empty vector (pcDNA3.1) was performed as a negative control. Forty-eight hours after the transfection, the cells were removed from the plates by scraping, washed with PBS, then 0.6% H 2 O 2 and 1.4% methanol was added for 30 min at 37°C. Then the cells were washed once more with PBS, and combined with rabbit antibody for L. interrogans serovar Lai, followed by HRPconjugated goat anti-rabbit immunoglobulin G, then diaminobenzidine, and observed using a microscope.
Western blot analysis
The transfected COS-7 cells were incubated in Laemmli sample buffer. Equal amounts of lysates were centrifuged (12,000 g, 5 min), and the supernatants were boiled for 10 min. Twenty microliters of the sample was loaded onto 8% sodium dodecyl sulfate (SDS) polyacrylamide gel, and subjected to electrophoresis. After the ninitrocellulose membrane was transferred, it was blocked with 5% nonfat milk in PBS at room temperature for 1 h. After which, the membrane was washed with PBST (PBS supplemented with 0.05% Tween) thrice, then incubated with 1:500 rabbit antibody for L. interrogans serovar Lai at 4°C overnight. Successively, after washing with PBST thrice, it was incubated with HRP-conjugated goat anti-rabbit immunoglobulin G for 1 h at room temperature, then the membrane was rinsed with PBST thrice. The bound antibodies were visualized by an enhanced chemilumine-scence (ECL) method using ECL Western blot detection reagents (8).
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DNA immunization
Forty-eight guinea pigs were randomly divided into three groups: one group was immunized with pcDNA3.1(+)-lipL21, another with pcDNA3.1(+), and the final group was injected with PBS. Six weeks after immunization, half of each group was sacrificed for detecting antibody and lymphocyte proliferation, and LipL21 was amplified through PCR from its muscle. The rest guinea pigs were reserved for the challenge. For each immunization, the guinea pig received two intramuscular injections of 100 μl (1 μg/μl) of vector containing pcDNA3.1(+)-lipL21 in the left quadriceps. The controls received an empty pcDNA3.1(+) or 100 μl PBS in the same conditions.
Serological analysis
Blood sample (1 ml) was collected every time from each guinea pig before immunization and at weeks 2, 4 and 6 after immunization. Specific serum antibodies were measured by MAT (microscopic agglutination test) using L. interrogans strain 56601 as antigen.
Lymphocyte proliferation assay
Splenocytes from each group (n = 8) were obtained, and cultured in 96-well flat-bottom with 0.2 ml of RPMI 1640 supplemented with 10% fetal bovine serum for 96 h. Then 20 μl MTT (2,5-di-phenyl-tetrazolium bromide) (5 mg/ml) was added into each well for 4 h (9). The blue crystals were dissolved by dimethyl sulfoxide at 37 o C for another 4 h. The light absorbance at 570 nm was measured by an automated microtiter plate reader.
Splenocytes were stimulated by PHA for 96 h, and the cells were stained through Wright staining. The rate of transformed cells was calculated immediately.
Challenge
Six weeks after the second immunization, another 8 guinea pigs from each group were challenged with 0.5 ml of a fresh culture of the virulent organism L. interrogans serovar lai by intraperitoneal injection. The guinea pigs were observed and the body weight was documented after the challenge daily. The surviving animals were sacrificed after 30 days. Necropsies were performed with special attention to liver, lung, and kidney lesions.
Results
PCR amplification of lipL21
PCR products of lipL21, about 560 bp, were amplified from L. interrogans Lai ( Figure 1A) . The similar products were also obtained from the guinea pigs immunized with pcDNAlipL21 ( Figure 1B) .
Identification of recombinant plasmid
Two fragments (about 2,800 bp and 560 bp) were acquired from pcDNA3.1(+)-lipL21 by digesting with Xho I and EcoR I (Figure 2) . The sequencing analysis indicated that it has no mispairing and frameshift mutation. pcDNA3.1(+)-lipL21/ liposome complex was transfected into COS-7 cells. After 30 h, the expression of lipL21 in COS-7 cells (in brown) was detected by immunocytochemistry. In contrast, normal COS-7 cells and COS-7 cells transfected with pcDNA3.1(+) did not expressed lipL21 (Figures 3) .
The total extracted proteins of transfected cells were used forSDS-PAGE analysis. A new protein ban about 21 kDa was found in the sample of COS-7 cells transfected with pcDNA3.1(+)-lipL21 recombinant plasmid ( Figure 4A ). Western blot analysis indicated that the antibody to L. interrogans serovar Lai could recognize the antigen, while no specific band was detected in the negative control group ( Figure 4B ).
Specific antibody increase in immunized guinea pigs
Specific antibodies were increased markedly in pcDNA3.1(+)- lipL21 immunized guinea pigs. Moreover, the antibody titers continued to rise with time. The highest titer reached 1:800 after 6 weeks post immunization. However, no antibody was detected in the control (Table 1) .
Proliferation of splenocytes to pcDNA3.1(+)-lipL21
After the guinea pigs were immunized with pcDNA3.1(+)-lipL21, the stimulation index (2.94 ± 0.25, n = 8) was significantly higher than those in pcDNA3.1(+) immunized group (1.52 ± 0.46) and PBS injected group (1.28 ± 0.25). Similarly, the lymphocyte transformation rate of the immunizing group (46.5%) was also obviously higher than those in control groups (21.0%, and 22.5%, p < 0.05) ( Table  2) .
Protection against L. interrogans by pcDNA3.1(+)-lipL21
Six weeks after the second immunization, the guinea pigs were challenged with L. interrogans serovar lai. All the animals survived after the challenge. The body weight of the guinea pigs immunized with pcDNA 3.1(+)-lipL21 was increased (6.25 ± 2.33 g). In contrast, the guinea pigs immunized with pcDNA3.1(+) or PBS exhibited abnormal thrix lofting and decrease in body weight (5.50 ± 1.02 g and 4.75 ± 0.87 g, respectively). Moreover, no obvious pathological changes were found in liver, kidneys, and lungs of the guinea pigs immunized with pcDNA3.1(+)-lipL21 ( Figure  5 ). However, some pathological changes, including edema of the liver cells and structural deformity of the hepatic cords, hemorrhage and hyperemia of the kidney, and hemorrhage of the lung, were observed in the guinea pigs immunized with pcDNA3.1(+) or PBS ( Figure 5 ).
Discussion
The aim of this study was to investigate and evaluate the protective effect of DNA vaccination with the lipL21 gene from L. interrogans serovars Lai in a model using guinea pigs challenged with serovar Lai. We constructed eukaryotic recombinant expression vector pcDNA3.1(+)-lipL21 and successfully transfected it into COS-7 cells. Our experiments illustrated that the guinea pigs immunized with pcDNA 3.1(+)-lipL21 were able to produce high titer of antibody to L. interrogans Lai. Moreover, the proliferation and transformation rate of its splenocytes increased obviously. pcDNA3.1(+)-lipL21 could stay in the guinea pigs for a substantially long period, and protect them from the challenge of L. interrogans Lai. LipL21 is the second most abundant protein in the L. interrogans serovar Lai outer membrane proteome (OMP) (7) . Western blot with LipL21 polyclonal antisera revealed that similar levels of LipL21 expression existed in 6 pathogenic leptospires, although they did not exist in nonpathogenic leptospires (7) . Correspondingly, the expression of LipL21 did not vary between the virulent and cultureattenuated strains. An alignment of the LipL21 sequences from six strains of pathogenic Leptospira revealed 96% to 100% identity. They also did not have any significant similarity with the proteins of other organisms (including other pathogenic spirochetes) (10) . These results indicate that LipL21 is a conserved leptospira OMP unique to the pathogenic strains and has potent immunity.
In human and veterinary medicine, vaccines need to overcome a large number of hurdles. Some of these hurdles include the cost of production, the ease of delivery and safety (11) . DNA vaccination has recently been tested for many pathogens. Thus far, it has exhibited some promising results (12) . It has been known that antigen-specific immune responses can be elicited by the intramuscular inoculation of a plasmid containing foreign DNA expressed (13, 14) . Likewise, DNA vaccines can induce potent humoral and cellular immune responses without any additional adjuvant (13) . The pcDNA3.1(+) vector includes CpG dilucleotides. Recent studies indicate that unmethylated CpG dinucleotides within DNA vaccines are immunostimulatory and exert an essential endogenous adjuvant activity (15) . These CpG motifs can be added deliberately to DNA vaccines to enhance Th1 immune response. In our case, after the guinea pigs' immunized with pcDNA3.1(+)-lipL21, the stimulation index of splenocytes was significantly higher than those in the control groups. The lymphocyte transformation rate of the immunized group was also obviously higher than those of the control groups. The titer of antibodies of MAT reached 1:800. Therefore, pcDNA3.1(+)-lipL21 can induce strong cellular immune response and humoral immunity. LipL21 was expressed in the COS-7 cells, thus indicating that the antigen could be presented very well to the immune system. The significant increase in antibody titer with subsequent boosters indicates that the lipL21 DNA vaccine can successfully generate enough protective antibodies to combat the pathogen.
The efficacy of any vaccine is gauged by its protective effects (16) . In our trial, all animals managed to survive including those in the control group. Other than the potency of the vaccine, it is highly probable that the virulence of the strain has decreased because it was a long-passage one. However, the liver, lungs and kidneys of immunized guinea pigs did not show any serious damage. In contrast, the control animals exhibited some lesion damages. Likewise, the immunized guinea pigs did not show any obvious clinical signs. This was not the case for the control animals which lost body weight and lofted thrix. These results indicate that the lipL21 DNA vaccine can effectively protect the immunized animals. The current available vaccines based on inactivated whole bacteria or membrane preparations from pathogenic leptospires have shown some drawbacks. These include very low efficacy, an unacceptable side-effect profile, the requirement for annual booster immunizations, and failure to confer cross-protective immunity against different serovars (2, 5, 17) . Generally, however, these vaccines do provide protection against the lethal onset of the disease, although they do not prevent persistent shedding from infected humans and animals (18) . Given that leptospira is an extracellular bacterium, protection was thought to be exclusively mediated by the humoral immune system (19) . Indeed, it is well documented that the anti-LPS antibody provides passive immunity in some animal models against a number of strains and species of leptospira (20) . However, anti-LigA antibodies failed to provide passive protection against the development of kidney lesions in hamsters (21) . Moreover, when used with adenovirus or DNA vaccine vectors, LipL32 provided significant protection in gerbils. However, it failed to provide sufficient protection when used as a recombinant protein vaccine (22, 23) . This may be due to the fact that recombinant protein can induce humoral immune response only, whereas delivery with adenovirus or DNA vaccine vector can stimulate both humoral and cell-mediated immunity. It has also been pointed out that cell-mediated immunity is required to fully protect against bovine leptospirosis (24) . Immunization with LigA DNA vaccine provides significant protection against leptospirosis (25) , and thus immunoprotection is conferred by both humoral and cellular immunity. Both OmpL1 (26) and endoflagellin (27) DNA vaccine can protect animals from the challenge of heterologous Leptospira spp as well. Therefore, the DNA vaccine may be an effective vaccine against Leptospira. If properly followed through, these works and our study could be helpful in designing and developing new generations of vaccines.
In conclusion, our results showed that the protective effect of Leptospira's pathogenic strains was shared by LipL21 as mediated by a plasmid vector. Consequently, we believe that the lipL21 DNA vaccine is a promising candidate for the prevention of leptospirosis.
